Page 175 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 175
89Zr-immuno-PET in a phase I trial
Supplemental Figure 3. Additional examples of focal tumor uptake of 89Zr-RG7356 at 96 h p.i.. From left to right: low dose CT, attenuation corrected PET and fused image. (a) Tumor lesion: left side of the skull (patient 8, 450mg cohort). (b) Tumor lesion: sacrum (patient 13, 675mg cohort).
Supplemental Table 1 Specific scoring criteria for CD44 expression in patient samples
Staining Intensity in tumor cells
3+ in >30% of tumour cells
2+ in >30% of tumor cells
2+ or 3+ in <30% of tumor cells (1+) or 1+ in >30% of tumor cells (1+) or 1+ in <30% of tumor cells No staining present in tumor cells Indeterminate
CD44 Scoring Assignment
Eligible for inclusion in trial
3 Yes 2 Yes 2 (focal) Yes 1 Yes 1 (focal) No
8
0
No
Determination of reactivity not possible. No Includes necrosis, no tumor present, no
tissue present, or artifacts.
173
